Search results
Showing 1 to 15 of 18 results for budesonide
Targeted release budesonide for treating IgA nephropathy [ID1434]
In development [GID-TA11028] Expected publication date: 20 December 2023
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in adults and children aged 12 and over.
This guideline covers the management of COVID-19 for babies, children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.
View recommendations for NG191Show all sections
Sections for NG191
Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in children under 12.
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
NG191/9 Question What is the clinical and cost effectiveness of budesonide for treating COVID 19 in the community in adults young people...
Question What is the clinical and cost effectiveness of prednisolone budesonide and beclometasone in addition to aminosalicylates...
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
This is a summary of the most common accessibility changes we are making in guidelines, and why
Show all sections
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
cover this group The committee made a recommendation against offering budesonide because evidence shows thatit is not beneficial in...
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making